Brief: Biostem Technologies Completes Enrollment In Clinical Trial Evaluating Bioretain® Amnion Chorion For Treatment Of Diabetic Foot Ulcers
23/06/2025 13:26
June 23 (Reuters) - Biostem Technologies Inc BSEM.PK: BIOSTEM TECHNOLOGIES COMPLETES ENROLLMENT IN CLINICAL TRIAL EVALUATING BIORETAIN® AMNION CHORION FOR TREATMENT OF DIABETIC FOOT ULCERS Source text: ID:nGNXlFXLV Further company coverage: BSEM.PK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioStem Technologies
See all newsBrief: Biostem Technologies Files Prospectus For Resale Of Up To 2.2 Mln Shares By Selling Stockholders - Filing
BioStem Technologies, Inc. reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Biostem Technologies Announces Appointment Of Three New Members To Its Board Of Directors